+

WO1996008258A1 - Antimicrobial composition - Google Patents

Antimicrobial composition Download PDF

Info

Publication number
WO1996008258A1
WO1996008258A1 PCT/FI1995/000493 FI9500493W WO9608258A1 WO 1996008258 A1 WO1996008258 A1 WO 1996008258A1 FI 9500493 W FI9500493 W FI 9500493W WO 9608258 A1 WO9608258 A1 WO 9608258A1
Authority
WO
WIPO (PCT)
Prior art keywords
rifampicin
bismuth
bismuth salt
rifamycin
antibiotic
Prior art date
Application number
PCT/FI1995/000493
Other languages
French (fr)
Inventor
Timo Juhani Pekkanen
Original Assignee
Orion-Yhtymä Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion-Yhtymä Oy filed Critical Orion-Yhtymä Oy
Priority to AU33884/95A priority Critical patent/AU3388495A/en
Publication of WO1996008258A1 publication Critical patent/WO1996008258A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/245Bismuth; Compounds thereof

Definitions

  • the present invention relates to antimicrobial pharmaceutical compositions and uses thereof for the treatment or prevention of staphylococcus infections. More particularly the invention relates to anti ⁇ microbial pharmaceutical compositions containing a bismuth salt and a rifamycin antibiotic agent for the treatment or prevention of staphylococcus infections.
  • Staphylococcus aur ⁇ us is encountered as a normal inhabitant of human skin and mucous membranes. However, it is responsible for a variety of clinical disorders in man and in animals ranging from pustules to fulminating septicemia.
  • rifamycin antibiotic agents such as rifabutin, rifamide, rifamycin sodium, rifapentine, rifaximin and rifampicin are complex macrocyclic antibiotics based on natural products of Streptomyces m ⁇ diterranei. They inhibit bacterial RNA synthesis by binding to DNA-dependent RNA polymerase.
  • Rifampicin (chemically 3-4(4-methylpiperazinylimino- methylidene)-rifamycin SV) is an extremely efficient inhibitor of the bacterial enzyme. It inhibits the growth of most gram-positive bacteria, as well as many gram-negative microorganisms and mycobacteria.
  • Rifamycin antibiotics especially rifampicin
  • rifampicin have been used frequently for therapy of selected staphylococcal infections in animals and humans.
  • In vitro rifampicin is extremely active against staphylococci, the growth is usually inhibited by rifampicin concentrations ⁇ 0.03 ⁇ g/ml.
  • mutants resistant to rifampicin can be detected both in vitro and in vivo amongst most of the bacteria usually sensitive to rifampicin.
  • S. aur ⁇ us has a propensity to rapidly acquire resistance to rifampicin after exposure to the agent as monotherapy.
  • the resistance is usually the result of one-step mutation which alters the ⁇ -subunit of RNA-polymerase, reducing its binding affinity for rifampicin.
  • the rapid development of resistance when rifampicin is used alone is a serious problem and greatly limits the usefulness of rifampicin in the treatment of e.g. 5. aureus infections.
  • the successive use of rifampicin in e.g. serious staphylococcal infections depends on the elimination of resistant variants present in the bacterial population.
  • Colloidal bismuth subcitrate and bismuth subsalicylate have been found to be useful in combination with ⁇ itroimidazole by preventing the development of aquired nitroimidazole resistance of H ⁇ licobact ⁇ r pylori (Axon, A. T. R., J. Gastroenterol. Hepatol., 1991, 6/2, 131 - 137).
  • the purpose of this invention is to overcome the problem of rapid development of rifampicin resistance in Staphylococcus by combining a bismuth salt with a rifamycin antibiotic agent. Further the purpose of this invention is to prepare antimicrobial pharmaceutical compositions containing a rifamycin antibiotic and a bismuth salt and thereby to inhibit the development of resistance.
  • the present invention provides an antimicrobial pharmaceutical composition
  • a rifamycin antibiotic agent and a bismuth salt in an amount suppressing the development of rifampicin resistance in Staphylococcus.
  • Staphylococcus infections which may be treated are preferably local rather than systemic infections and include e.g. S. aureus and 5. epidermis.
  • compositions according to the invention include for example granulates, tablets, capsules, dragees, powders, ointments, gels, emulsions, suspensions and infusions (solutions) and can be administered for example orally, rectally, topically or by bladder infusion. Both agents are preferably administered concurrently, but the pharmaceutical effect of the present composition will be present if both agents exist concurrently for a certain duration in the body, particularly at the infection site.
  • the second of the two agents to be administered may be administered within the metabolic half life at the infection site of the first agent to be administered. So, the bismuth salt can be administered sequentially, separately or simultaneously with the rifamycin antibiotic. These two agents can be administered via different routes, for example rifamycin antibiotic orally and bismuth salt topically.
  • compositions according to the invention may be formulated and employed in the usual manner. These compositions are particularly well-suited for ophthalmic, otic or topical uses (gels, ointments, powders, sprays and aqueous or oily emulsions and suspensions), but could also find other applications.
  • topical use of bismuth salts is preferred. Systemic treatment of infections with bismuth salts is not recommended because of the possibility of serious side effects. Nausea and vomiting as well as darkening of the tongue have been reported. Further, the possibility of bismuth encephalopathy exists after prolonged use (Martindal ⁇ , The Extra
  • the concentration of a bismuth salt in a pharmaceutical preparation containing also rifampicin should be in the range of 5 - 3000 ⁇ g/ml e.g. 5 to 400 ⁇ g/ml. The effect is not concentration dependent and at low bacterial densities even a relatively low bismuth salt concentration may be sufficient.
  • the weight ratio of a bismuth salt to rifamycin is preferably between 1 :0.0003 - 1 :50 e.g. 1 :0.0003 to 1 :20, particularly 1 :0.0003 to 1:0.625.
  • compositions containing the active combination may also be used in veterinary medicine.
  • compositions according to the present invention are applicable also in the treatment of certain infections caused by either Staphylococcus or Ps ⁇ udomonas such as hospital infections which in many instances are extremely resistant to antibiotics.
  • the most common hospital infections are the urinary tract and wound infections where the causative agent is often Ps. aeruginosa or S. aureus. Because of the possibility that these two bacteria are simultaneously present at the infection site, the use of the present combination is especially advantageous for the treatment of this kind of infections / these kinds of infection.
  • FRI-1104 was obtained from Food Research Institute (FRI), Madison, USA and strains 2 - 12 (ATCC-12600, ATCC-8096, ATCC-25923, ATCC-25178, ATCC-8095, ATCC-27664, ATCC-13565, ATCC-19095, ATCC-14458, ATCC- 27154 and ATCC-6538) were obtained from American Type Culture Collection (ATCC), Maryland, USA. All strains were tested by the broth microdilution method for sensitivity of rifampicin. The minimum inhibitory concentration (MIC) was for all strains ⁇ 0.008 ⁇ g/ml. The strains were similarily tested for their sensitivity of bismuth subcitrate. The MIC for strain 5 was found to be 800 ⁇ g/ml and for the others the MIC-values were ⁇ 3200 ⁇ g/ml.
  • the success rate of developing rifampicin resistance after exposure to rifampicin, rifampicin together with bismuth subcitrate, bismuth subcitrate or nil was performed by suspending S. aureus organisms to a density of about 1- 10 10 cfu/ml in Mueller-Hinton (MH) broth containing 0.1 ⁇ g/ml rifampicin, 0.1 ⁇ g/ml rifampicin together with 400 ⁇ g/ml bismuth subcitrate, 400 ⁇ g/ml bismuth subcitrate or no additions, respectively.
  • MH Mueller-Hinton
  • the results are summarized in tables 1 and 2.
  • the first column (rif) in both tables shows the log cfu/ml of the 12 strains of S. aureus resistant to either 0.1 ⁇ g/ml (table 1) or 1 ⁇ g/ml (table 2) rifampicin recovered after exposure to 0.1 ⁇ g/ml rifampicin for 18 h over the log cfu/ml of total viable organisms.
  • the second column (rif+bic) shows correspondingly the log cfu/ml of the resistant organisms over the log cfu/ml of the total viable organisms after exposure to 0.1 ⁇ g/ml rifampicin together with 400 ⁇ g/ml bismuth subcitrate.
  • the third column (bic) shows the log cfu/ml of the rifampicin resistant staphylococci over the log cfu/ml of the total viable organisms after exposure to 400 ⁇ g/ml bismuth subcitrate only.
  • the fourth column (nil) shows the log cfu/ml of the rifampicin resistant organisms over the log cfu/ml of the total viable organisms after exposure only to MH-broth.
  • the MIC-values were obtained with an inoculum of 10 5 cfu/ml while the initial bacterial density in the exposure studies was about 10 10 cfu/ml.
  • the exposure of bismuth subcitrate alone did not significantly affect the total number of vialble organisms or have any clear effect on the number of rifampicin resistant organisms.
  • the comparison of the second (rif+bic) and the fourth (nil) columns in the tables shows that among most of the strains (except perhaps strains 11 and 12) the development of new resistant organisms was possibly totally inhibited by bismuth subcitrate.
  • bismuth subcitrate The effects of bismuth subcitrate were measured by using a maximum bismuth subcitrate concentration of 400 ⁇ g/ml on a bacterial density of about 10 10 cfu/ml. Higher concentrations were avoided because they could have generally suppressed the growth of staphylococci. To have an effect on the development of resistance bismuth salt must apparently react with the individual bacteria. The concentration of bismuth salt that is required for the effect seen thus obviously depends also on the number of bacteria in the study medium. Further, even relatively low bismuth subcitrate concentrations can suppress the emergence of resistance among staphylococci if the density of bacteria in the study system is low enough. Table 1.
  • a topical ointment or gel formulation according to the present invention is prepared by combining rifampicin (0.005 %) and bismuth subcitrate (0.02%) with an appropriate ointment or gel base and with necessary additives.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Staphylococcus infections may be treated or prevented by the administration sequentially, separately or simultaneously of a bismuth salt and a rifamycin antibiotic. Rifamycin resistance is inhibited.

Description

ANTIMICROBIAL COMPOSITION
TECHNICAL FIELD OF THE INVENTION
The present invention relates to antimicrobial pharmaceutical compositions and uses thereof for the treatment or prevention of staphylococcus infections. More particularly the invention relates to anti¬ microbial pharmaceutical compositions containing a bismuth salt and a rifamycin antibiotic agent for the treatment or prevention of staphylococcus infections.
BACKGROUND OF THE INVENTION
Staphylococcus aurβus is encountered as a normal inhabitant of human skin and mucous membranes. However, it is responsible for a variety of clinical disorders in man and in animals ranging from pustules to fulminating septicemia.
The rifamycin antibiotic agents, such as rifabutin, rifamide, rifamycin sodium, rifapentine, rifaximin and rifampicin are complex macrocyclic antibiotics based on natural products of Streptomyces mβditerranei. They inhibit bacterial RNA synthesis by binding to DNA-dependent RNA polymerase. Rifampicin (chemically 3-4(4-methylpiperazinylimino- methylidene)-rifamycin SV) is an extremely efficient inhibitor of the bacterial enzyme. It inhibits the growth of most gram-positive bacteria, as well as many gram-negative microorganisms and mycobacteria.
Rifamycin antibiotics, especially rifampicin, have been used frequently for therapy of selected staphylococcal infections in animals and humans. In vitro rifampicin is extremely active against staphylococci, the growth is usually inhibited by rifampicin concentrations ≤ 0.03 μg/ml. However, mutants resistant to rifampicin can be detected both in vitro and in vivo amongst most of the bacteria usually sensitive to rifampicin. For example S. aurβus has a propensity to rapidly acquire resistance to rifampicin after exposure to the agent as monotherapy. The resistance is usually the result of one-step mutation which alters the β-subunit of RNA-polymerase, reducing its binding affinity for rifampicin. The rapid development of resistance when rifampicin is used alone is a serious problem and greatly limits the usefulness of rifampicin in the treatment of e.g. 5. aureus infections. The succesful use of rifampicin in e.g. serious staphylococcal infections depends on the elimination of resistant variants present in the bacterial population.
To overcome the problem of rapid emergence of resistant bacteria during a treatment with rifampicin alone in S. aureus infections, combinations with other antibiotics are recommended although they do not necessarily inhibit the development of resistant mutants. Further, of the various antibiotics tested with rifampicin only nafcillin, novobiocin and teicoplanin have been found to suppress the emergence of rifampicin resistance in S. aureus (Eng et al., J. Antimicrob. Chemother.,1985, 15, pp. 201 - 207 and Dixson et al., Eur. J. Clin. Microbiol., 1985; 4/1, 19 - 23).
Colloidal bismuth subcitrate and bismuth subsalicylate have been found to be useful in combination with πitroimidazole by preventing the development of aquired nitroimidazole resistance of Hθlicobactβr pylori (Axon, A. T. R., J. Gastroenterol. Hepatol., 1991, 6/2, 131 - 137).
In vitro synergistic activity of the combination of bismuth subcitrate and rifampicin against Hβlicobactβr pylori has been demonstrated (D.L. Van
Caekenberghe, J. Breyssens; Antimicrobial Agents and Chemotherapy, 1987, 31/9: 1429-1430).
There are no reports concerning the effect of bismuth salts on the development of resistance against antibiotics in staphylococci.
DISCLOSURE OF THE INVENTION
The purpose of this invention is to overcome the problem of rapid development of rifampicin resistance in Staphylococcus by combining a bismuth salt with a rifamycin antibiotic agent. Further the purpose of this invention is to prepare antimicrobial pharmaceutical compositions containing a rifamycin antibiotic and a bismuth salt and thereby to inhibit the development of resistance.
When bismuth subcitrate was combined with rifampicin, it was unexpectedly found that the development of resistance against rifampicin was suppressed or totally inhibited among S. aureus whereby the effective doses of these substances could be decreased noticeably.
Thus, the present invention provides an antimicrobial pharmaceutical composition comprising a rifamycin antibiotic agent and a bismuth salt in an amount suppressing the development of rifampicin resistance in Staphylococcus.
Staphylococcus infections which may be treated are preferably local rather than systemic infections and include e.g. S. aureus and 5. epidermis.
The pharmaceutical compositions according to the invention include for example granulates, tablets, capsules, dragees, powders, ointments, gels, emulsions, suspensions and infusions (solutions) and can be administered for example orally, rectally, topically or by bladder infusion. Both agents are preferably administered concurrently, but the pharmaceutical effect of the present composition will be present if both agents exist concurrently for a certain duration in the body, particularly at the infection site. For example, the second of the two agents to be administered may be administered within the metabolic half life at the infection site of the first agent to be administered. So, the bismuth salt can be administered sequentially, separately or simultaneously with the rifamycin antibiotic. These two agents can be administered via different routes, for example rifamycin antibiotic orally and bismuth salt topically.
The pharmaceutical compositions according to the invention may be formulated and employed in the usual manner. These compositions are particularly well-suited for ophthalmic, otic or topical uses (gels, ointments, powders, sprays and aqueous or oily emulsions and suspensions), but could also find other applications. However, topical use of bismuth salts is preferred. Systemic treatment of infections with bismuth salts is not recommended because of the possibility of serious side effects. Nausea and vomiting as well as darkening of the tongue have been reported. Further, the possibility of bismuth encephalopathy exists after prolonged use (Martindalβ, The Extra
Pharmacopoeia, ed. by James E.F. Reynolds, 30th ed. The Pharmaceutical Press, London, 1993, p. 909).
The concentration of a bismuth salt in a pharmaceutical preparation containing also rifampicin should be in the range of 5 - 3000 μg/ml e.g. 5 to 400 μg/ml. The effect is not concentration dependent and at low bacterial densities even a relatively low bismuth salt concentration may be sufficient. In topical ointments, powders, gels, rinsing solutions, eye and ear drops and wound dressings etc. the weight ratio of a bismuth salt to rifamycin is preferably between 1 :0.0003 - 1 :50 e.g. 1 :0.0003 to 1 :20, particularly 1 :0.0003 to 1:0.625.
The pharmaceutical compositions containing the active combination may also be used in veterinary medicine.
Further, the compositions according to the present invention are applicable also in the treatment of certain infections caused by either Staphylococcus or Psθudomonas such as hospital infections which in many instances are extremely resistant to antibiotics. The most common hospital infections are the urinary tract and wound infections where the causative agent is often Ps. aeruginosa or S. aureus. Because of the possibility that these two bacteria are simultaneously present at the infection site, the use of the present combination is especially advantageous for the treatment of this kind of infections / these kinds of infection.
In veterinary clinical praxis a common disease in dogs is otrtis externa which is often caused by Ps. aeruginosa or S. aureus. Because of the difficulty of reliable laboratory diagnosis it is advantageous to treat the infection with the present combination which has a good effect on both types of bacteria.
Examples of bismuth salts which may be used in accordance with present invention include bismuth subcitrate, bismuth subnitrate and bismuth subsalicyiate. Bismuth subcitrate is preferred.
The following examples are presented to further illustrate the present invention. They should not be interpreted as limiting the scope of the invention in any way. EXAMPLE 1 ,
Comparison of the number of Staphylococcus resistant to rifampicin recovered after exposure in MH-broth to rifampicin. rifampicin + bismuth subcitrate. bismuth subcitrate and nil.
Twelve strains of S. aureus were used in the experiment. Strain 1
(FRI-1104) was obtained from Food Research Institute (FRI), Madison, USA and strains 2 - 12 (ATCC-12600, ATCC-8096, ATCC-25923, ATCC-25178, ATCC-8095, ATCC-27664, ATCC-13565, ATCC-19095, ATCC-14458, ATCC- 27154 and ATCC-6538) were obtained from American Type Culture Collection (ATCC), Maryland, USA. All strains were tested by the broth microdilution method for sensitivity of rifampicin. The minimum inhibitory concentration (MIC) was for all strains ≤ 0.008 μg/ml. The strains were similarily tested for their sensitivity of bismuth subcitrate. The MIC for strain 5 was found to be 800 μg/ml and for the others the MIC-values were ≥3200 μg/ml.
The success rate of developing rifampicin resistance after exposure to rifampicin, rifampicin together with bismuth subcitrate, bismuth subcitrate or nil was performed by suspending S. aureus organisms to a density of about 1- 1010 cfu/ml in Mueller-Hinton (MH) broth containing 0.1 μg/ml rifampicin, 0.1 μg/ml rifampicin together with 400 μg/ml bismuth subcitrate, 400 μg/ml bismuth subcitrate or no additions, respectively. After incubating 18 h at 37 °C, an amount of 0,1 ml of each incubation mixture was quantitatively subcultured on plain MH-agar and on MH-agar containing 0.1 or 1 μg/ml rifampicin. The number of viable organisms which appeared on the agars after an overnight incubation at 37 °C was determined.
The results are summarized in tables 1 and 2. The first column (rif) in both tables shows the log cfu/ml of the 12 strains of S. aureus resistant to either 0.1 μg/ml (table 1) or 1 μg/ml (table 2) rifampicin recovered after exposure to 0.1 μg/ml rifampicin for 18 h over the log cfu/ml of total viable organisms. The second column (rif+bic) shows correspondingly the log cfu/ml of the resistant organisms over the log cfu/ml of the total viable organisms after exposure to 0.1 μg/ml rifampicin together with 400 μg/ml bismuth subcitrate. The third column (bic) shows the log cfu/ml of the rifampicin resistant staphylococci over the log cfu/ml of the total viable organisms after exposure to 400 μg/ml bismuth subcitrate only. And the fourth column (nil) shows the log cfu/ml of the rifampicin resistant organisms over the log cfu/ml of the total viable organisms after exposure only to MH-broth.
The success rate of development of rifampicin resistance after the various exposures (results given in tables 1 and 2) shows that all the 12 S. aureus strains developed resistance against both 0.1 μg/ml and 1 μg/ml rifampicin after 18 h exposure to 0.1 μg/ml rifampicin. The fact that the bacteria did not die during the exposure although their MICs of rifampicin were as low as ≤ 0.008 μg/ml can be partly explained by the well known inoculum effect (Chapman, R. and Steigbiegel, R., 1975, J. Infect .Dis., 147, 156 - 163). The MIC-values were obtained with an inoculum of 105 cfu/ml while the initial bacterial density in the exposure studies was about 1010 cfu/ml. When studying the first (rrf) and the second (rif+bic) columns in tables 1 and 2 'it can be seen that the emergence of rifampicin resistance was suppressed when the bacteria were exposed to both rifampicin and bismuth subcitrate. The exposure of bismuth subcitrate alone did not significantly affect the total number of vialble organisms or have any clear effect on the number of rifampicin resistant organisms. The comparison of the second (rif+bic) and the fourth (nil) columns in the tables shows that among most of the strains (except perhaps strains 11 and 12) the development of new resistant organisms was possibly totally inhibited by bismuth subcitrate.
The mechanism behind the effect of bismuth subcitrate remain obscure. Rifampicin resistance is primarily caused by alteration in the bacterial RNA- polymerase (Wehrli, W., 1983, Rev. Infect. Dis., 5 (suppl.3), 407 - 411). A change of one amino acid in the subunit causes resistance. This change is apparently inhibited by bismuth salt.
The effects of bismuth subcitrate were measured by using a maximum bismuth subcitrate concentration of 400 μg/ml on a bacterial density of about 1010 cfu/ml. Higher concentrations were avoided because they could have generally suppressed the growth of staphylococci. To have an effect on the development of resistance bismuth salt must apparently react with the individual bacteria. The concentration of bismuth salt that is required for the effect seen thus obviously depends also on the number of bacteria in the study medium. Further, even relatively low bismuth subcitrate concentrations can suppress the emergence of resistance among staphylococci if the density of bacteria in the study system is low enough. Table 1.
Strain Number of rifampicin resistant organisms / total No: number of organisms after exposure to (log cfu/ml)
Figure imgf000009_0001
1 7.1 / 9.4 4.9 /10.3 2.8 /10.3 5.5/10.6
2 3.6 /10.4 1.8 /9.4 1.2 /9.3 2.9 / 10.4
3 5.2 /10.2 2.4 /10.0 2.9 / 9.9 3.8 / 10.2
4 7.2 /10.5 2.9 /10.3 2.8 /10.3 3.2/10.3
5 5.5 /7.1 1.2 /6.7 1.4 /6.0 2.1 /6.5
6 7.2 /10.6 3.2 /10.4 3.0 /10.3 3.4 / 10.6
7 4.8 /10.3 2.1 /10.0 2.0 / 9.7 2.8/10.2
8 6.9 /10.3 2.4 /10.2 2.1 / 10.1 3.0 / 10.2
9 6.5 /10.0 3.4 /9.8 2.1 /9.5 2.9/9.6
10 3.8 /10.4 2.5 /9.6 1.9 /9.6 2.9 / 10.2
11 7.6 /10.3 5.7 / 9.9 2.4 /10.1 2.9/10.3
12 10.4/10.4 4.4 /10.2 2.5 /10.2 3.1 / 10.5
8
Table 2-
Strain Number of rifampicin resistant organisms / total No: number of organisms after exposure to (log cfuml) if rf+bic bfc ri
1 7.1 /9.4 4.2 /10.3 2.4 /10.3 5.1 /10.6
2 3.5 /10.4 1.4 /9.4 1.3 /9.3 2.8 /10.4
3 3.0 /10.2 1.9 /10.0 2.7 /9.9 3.5 /10.2
4 7.2 /10.5 2.4 /10.3 2.4 /10.3 2.7 / 10.3
5 5.6 /7.1 1.2 /6.7 2.2 /6.0 2.0 /6.5
6 7.0 /10.6 2.8 /10.4 2.4 /10.3 3.1 /10.6
7 4.9 /10.3 1.2 /10.0 1.3 /9.7 2.4 / 10.2
8 6.8/10.3 2.6 /10.2 1.8 / 10.1 2.7 / 10.2
9 6.4 /10.0 3.4 /9.8 1.0 /9.5 2.3 /9.6
10 2.9 /10.4 2.3 / 9.6 1.4 /9.6 2.7 / 10.2
11 7.6 /10.3 5.8 / 9.9 2.3 /10.1 2.7 / 10.3
12 3.1 /10.4 ND/10.2 2.3 /10.2 2.6 / 10.5
EXAMPLE 2
Concentration dependence To study the effect of the concentration of bismuth subcitrate on the development of rifampicin resistance in S. aureus strain 4 was suspended and incubated in MH-broth as discribed in example 1. The broth contained either no addition or 0.1 μg/ml rifampicin or 0.1 μg/ml rifampicin and 50, 100, 200 or 400 μg/ml bismuth subcitrate. An amount of 0.1 ml of each incubation mixture was quantitatively subcultured on MH-agar as described in example 1 except that plates containing 0.1 μgml rifampicin were omitted. The number of viable organisms after an overnight incubation at 37 °C was determined.
The comparative effect of 5 different bismuth subcitrate concentrations (0, 50, 100, 200 and 400 μg/ml ) on the development of rifampicin resistance in S. aureus strain 4 during an overnight incubation with 0.1 μg/ml rifampicin in MH-broth is presented in table 3.
The results in table 3 do not show any concentration dependent effect of bismuth subcitrate on the development of resistance to rifampicin on S. aureus. These results further show that the number of organisms resistant to rifampicin after overnights exposure to 0.1 μg/ml rifampicin plus 50 - 400 μg/ml bismuth subcitrate do not significantly differ from the number of resistant organisms recovered after overnights incubation in the plain MH-broth. This suggests that bismuth subcitrate totally inhibited the development of rifampicin resistance due to rifampicin exposure on the studied S. aureus strain.
Table 3.
Exposure Number of rifampicin resistant / total number of organisms (log cfu/ml)
Rrf 8.6 / 10.6
Rif + 50 μgAπl BiC 2.7 / 10.6
RH + 100 μg/ml BIC 3.0 / 10.4
Rif + 200 μg/ml BIC 2.6 / 10.3
Rif + 400 μg/ml BIC 2.6 / 10.5 plain MH-broth 2.9 / 10.6
EXAMPLE 3, Ointment or gel formulation for the treatment of skin infections Of
W£U0 £
A topical ointment or gel formulation according to the present invention is prepared by combining rifampicin (0.005 %) and bismuth subcitrate (0.02%) with an appropriate ointment or gel base and with necessary additives.

Claims

1. A product which is an antimicrobial pharmaceutical composition comprising a rifamycin antibiotic and bismuth salt for use in the treatment of Staphylococcus infections.
2. A product comprising (i) a rifamycin antibiotic and (ii) a bismuth salt as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a Staphylococcus infection.
3. A product according to claim 1 or 2 wherein the bismuth salt is bismuth subcitrate, bismuth subsalicylate or bismuth nitrate.
4. A product according to claim 3 wherein the bismuth salt is bismuth subcitrate.
5. A product according to any one of claims 1 to 4 wherein the rifamycin antibiotic is rifampicin.
6. A product according to claim 5 wherein the ratio of bismuth salt to rifamycin antibiotic is from 1 :0.0003 to 1 :50.
7. A product according to any one of claims 1 to 6 wherein the bismuth salt is in a form suitable for administration simultaneously with the antibiotic agent.
8. A product according to any one of claims 1 to 6 wherein the bismuth salt is in a form suitable for administration separately from the antibiotic agent.
9. Use of a bismuth salt and a rifamycin antibiotic in the manufacture of a medicament for use in the treatment of a Staphylococcus infection.
10. A method of treatment or prevention of a Staphylococcus infection comprising administering to a subject an effective amount of a bismuth salt and an effective amount of a rifamycin antibiotic.
11. A pharmaceutical or veterinary formulation comprising as active ingredients a rifamycin antibiotic and a bismuth salt formulated for pharmaceutical or veterinary use respectively.
PCT/FI1995/000493 1994-09-12 1995-09-12 Antimicrobial composition WO1996008258A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33884/95A AU3388495A (en) 1994-09-12 1995-09-12 Antimicrobial composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418345A GB2292884A (en) 1994-09-12 1994-09-12 Rifamycin & bismuth salts for treating bacterial infections
GB9418345.6 1994-09-12

Publications (1)

Publication Number Publication Date
WO1996008258A1 true WO1996008258A1 (en) 1996-03-21

Family

ID=10761198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1995/000493 WO1996008258A1 (en) 1994-09-12 1995-09-12 Antimicrobial composition

Country Status (3)

Country Link
AU (1) AU3388495A (en)
GB (1) GB2292884A (en)
WO (1) WO1996008258A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100572090B1 (en) * 1998-02-24 2006-04-17 액티브 바이오틱스 인코포레이티드 Synergistic antimicrobial compositions, medicaments containing the same and agents for treating digestive diseases, methods for their preparation, and agents related thereto
RU2632766C1 (en) * 2016-07-26 2017-10-09 Общество с ограниченной ответственностью "Медико-инженерный центр + 16" Antimicrobial tympanic shunt

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000147A1 (en) * 1993-06-28 1995-01-05 Merck & Co., Inc. 4-AZA-PREGNANE 5α-REDUCTASE ISOZYME 1 INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650787T2 (en) * 1985-06-13 2006-11-16 Dr. Barry James Marshall A pharmaceutical composition for the treatment of gastrointestinal disorders containing bismuth and an antimicrobial agent
CN1057001A (en) * 1991-07-13 1991-12-18 沈阳市红旗制药厂 The preparation method of anti-enteritis capsule
CN1080529A (en) * 1992-06-23 1994-01-12 沈阳市光华兽药厂 The manufacture method of dysentery medicine (Salibao)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000147A1 (en) * 1993-06-28 1995-01-05 Merck & Co., Inc. 4-AZA-PREGNANE 5α-REDUCTASE ISOZYME 1 INHIBITORS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J.CLIN.ENDOCRINOL.METAB., vol. 70, no. 4, 1990 pages 1136-41, 'Effects of finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating androgens in male volunteers' *
METABOLISM, vol. 39, no. 9, 1990 pages 919-24, 'HDL response to 5-alpha dihydrotestosterone and testosterone in Macaca Fascicularis: a hormone-responsive primate model for the study of atherosclerosis' *
PHARMACOMETRICS, vol. 47, no. 3, 1994 'Androgen Osaterone Acetate (TZP-4238)' *

Also Published As

Publication number Publication date
AU3388495A (en) 1996-03-29
GB9418345D0 (en) 1994-11-02
GB2292884A (en) 1996-03-13

Similar Documents

Publication Publication Date Title
JP2676080B2 (en) Non-antibacterial tetracycline composition
MANGI et al. Development of meningitis during cephalothin therapy
RU2560846C1 (en) Pharmaceutical compositions, containing sulbactam and beta-lactamase inhibitor
JPH0780774B2 (en) Pharmaceutical composition
Reeves Sulphamethoxazole-trimethoprim: the first two years
Yeldandi et al. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus
Scheld et al. Comparison of netilmicin with gentamicin in the therapy of experimental Escherichia coli meningitis
Portnoy et al. Penicillin tolerance of human isolates of group C streptococci
Guerrant et al. Nosocomial bloodstream infections caused by gentamicin-resistant gram-negative bacilli
Elwell et al. In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus
Kuenzi et al. Postantibiotic effect of roxithromycin, erythromycin, and clindamycin against selected gram-positive bacteria and Haemophilus influenzae
Figueredo et al. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis
CN109481439A (en) Composition comprising antibacterial agent and Tazobactam Sodium
JPH07188030A (en) Moenomycin for preparing drug, its derivative, and drug containing these
Yogev et al. In vitro activity of antibiotics alone and in combination against Actinobacillus actinomycetemcomitans
CN1054745C (en) Antibiotic combination
WO1996008258A1 (en) Antimicrobial composition
US3949077A (en) Synergistic antibiotic compositions
WO2024187962A1 (en) Use of su3327 in preparation of drug for reducing cytotoxicity and renal toxicity of polymyxin
Iravani et al. Effects of changes in pH, medium, and inoculum size on the in vitro activity of amifloxacin against urinary isolates of Staphylococcus saprophyticus and Escherichia coli
Day et al. Increased susceptibility of Pseudomonas aeruginosa to ciprofloxacin in the presence of vancomycin
Vilmgnyi et al. Clarithromycin pharmacokinetics after oral administration with or without fasting in crossbred beagles
Brumfitt et al. General survey of trimethoprim combinations in the treatment of urinary tract infections
WO1996008259A1 (en) Synergistic antimicrobial composition
Louie et al. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KZ LT LU LV MK MX NO NZ PL PT RO RU SE SI SK UA US UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载